The effect of furosemide dose timing on bladder activity in oncology imaging with 18F-fluorodeoxyglucose PET/CT

Nuclear Medicine Communications

Volumn 31, Issue 2, 2010, Pages 167-172

  Nijjar, Sundeep ^a   Patterson, Judy ^a   Ducharme, Jaylene ^a   Leslie, William D ^a,b   Demeter, Sandor J ^a,b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

18F fluorodeoxyglucose, furosemide, positron emission tomography, urinary bladder

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE;

ADULT; ARTICLE; BLADDER CAPACITY; BLADDER FUNCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; POSITRON EMISSION TOMOGRAPHY; URINARY URGENCY;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORODEOXYGLUCOSE F18; FUROSEMIDE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; MALE; MIDDLE AGED; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 75149165703     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833492eb     Document Type: Article

References (23)

1. De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, Bonomo L. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. Abdom Imaging 2009; 34: 696-711.
2. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK,Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 2005; 25:1031-1043.
3. Pandit-Taskar N. Oncological imaging in gynecological malignancies. J Nucl Med 2005; 46:1842-1850.
4. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20:379-387.
5. Avril N, Menzel M, Dose J, Schelling M,Weber W, Jä nicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
6. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma, and melanoma. J Nucl Med 1999; 4: 591-603.
7. Higashi K, Ueda Y, Sakuma T, Seki H, Oguchi M, Taniguchi M, et al. Comparison of [18F]FDG PET and 201Tl SPECT in evaluation of pulmonary nodules. J Nucl Med 2001; 42:1489-1496.
8. Acton PD, Zhuang H, Alavi A. Quantification in PET. Radiol Clin N Am 2004; 42:1055-1062.
9. Miller JH, Mullin JM, McAvoy E, Kleinzellar A. Polarity of transport of 2-deoxy- D-glucose and D-glucose by cultured renal epithelia. Biochem Biophys Acta 1992; 1110:209-217.
10. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR,Wan CN,Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-Dglucose. J Nucl Med 1978; 19:1154-1161.
11. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK,Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 2005; 25:1031-1043.
12. Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005; 33:145-155.
13. Koyama K, Okamura T, Kawabe J, Ozawa N, Torii K, Umesaki N, et al. Evaluation of 18F-FDG with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 2003; 44:353-358.
14. Vessell HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathological conditions, and strategies to avoid diagnostic pitfalls. Radiographics 1998; 19:805-823.
15. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997; 24: 615-620.
16. Kamel EM, Jichlinski P, Prior JO, Meuwly JY, Delaloye JF, Vaucher L, et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 2006; 47:1803-1807.
17. Diehl M, Manolopoulou M, Risse J, Kranert T, Menzel C, Dobert N, Grunwald F. Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide. Acta Medica Austriaca 2004; 31:76-78.
18. Mantzarides M, Papathanassiou D, Bonardel G, Soret M, Gontier E, Foehrenbach H. High grade lymphoma of the bladder visualized on PET. Clin Nucl Med 2005; 30:478-480.
19. Anjos DA, Etchebehere E, Ramos C, Sandos AO, Alberotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007; 48:764-770.
20. Lopez-Gandul S, Perez-Moure G, Garcia-Garzon JR, Soler-Peter M, Simo- Perdigo M, Lomena F. Intravenous furosemide injection during 18F-FDG PET acquisition. J Nucl Med Technol 2006; 34:228-231.
21. Nair N, Basu S. Selected cases demonstrating the value of furosemideprmed 18F-FDG PET in identifying adrenal involvement. J Nucl Med Technol 2005; 33:166-171.
22. Cook GJR. Artifacts and normal variants in whole-body PET images. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, editors. Positron emission tomography: basic science and clinical practice. London, UK: Springer- Verlag; 2003, pp. 495-505.
23. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2009. Toronto, Canada: Canadian Cancer Society 2009.